Sarda Proteins Limited approved a rights issue of equity shares amounting to up to ₹1,000 crore during its Board of Directors meeting held on August 5, 2026. The move allows existing shareholders to purchase additional fully paid-up equity shares with a face value of ₹10 each. This capital raise represents a significant financing step for the meat processing company, aiming to strengthen its balance sheet or fund expansion plans, though specific utilization details were not disclosed in the filing. Shareholders must wait for the record date notification to determine eligibility.

The Board approved the issuance in accordance with the Companies Act, 2013, and the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. Concurrently, the directors authorized the filing of the Draft Letter of Offer (DLOF) with the Securities and Exchange Board of India (SEBI) and relevant stock exchanges. Procedural compliance was maintained under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

To oversee the execution of the capital raise, the Board constituted a Rights Issue Committee. This committee is tasked with managing all matters related to the proposed issue under applicable laws. The committee comprises three key directors from the company’s leadership team.

In a separate development during the same meeting, the Board noted the resignation of non-executive director Gunvantray Jayantilal Zaladi. His resignation takes effect from the close of business hours on August 5, 2026. In his resignation letter dated August 5, 2026, Mr. Zaladi cited personal reasons and pre-occupations as the cause for stepping down. He confirmed there were no material reasons for his departure other than those stated.

The company will separately intimate the record date for the rights issue once finalized, as required under Regulation 42 of the SEBI Listing Regulations. Investors are advised to monitor official communications from Sarda Proteins Limited for further updates regarding the timeline and application process for the rights issue.

Sarda Proteins Limited reported a standalone net profit of ₹68.60 lakh for the quarter ended March 31, 2026 (Q4FY26), marking a significant turnaround from a net loss of ₹11.23 lakh in the corresponding quarter of FY25. The Alwar-based renewable energy player also posted a full-year net profit of ₹45.44 lakh for FY26, up from ₹0.50 lakh in FY25. The improved profitability was supported by higher interest income and operational efficiencies, while the company executed a major equity raise that substantially strengthened its balance sheet.

The Board of Directors approved the audited financial results in a meeting held on April 30, 2026. Sarda Proteins subsequently submitted revised results to the BSE on August 05, 2026, citing clerical corrections related to the booking of interest income and the reclassification of share warrants as equity. The company stated that these revisions do not have a material impact on its overall financial position.

Financial Performance

Revenue from operations for Q4FY26 stood at ₹65.00 lakh, compared to nil in Q4FY25. For the full year FY26, revenue from operations was ₹1,615.84 lakh, down from ₹2,419.10 lakh in FY25. However, other income surged to ₹34.90 lakh for the year, up from ₹0.06 lakh in the previous year, primarily due to interest income. Total expenses for Q4FY26 were ₹5.26 lakh, resulting in a profit before tax of ₹84.10 lakh. After providing for current tax expenses of ₹15.50 lakh, the net profit for the quarter came in at ₹68.60 lakh.

Balance Sheet and Cash Flow

The company’s balance sheet underwent a significant transformation during FY26. Total assets rose to ₹8,665.52 lakh as of March 31, 2026, from ₹264.81 lakh at the end of FY25. This increase was largely driven by cash and cash equivalents, which jumped to ₹751.92 lakh from ₹3.38 lakh, and other current assets (advances), which stood at ₹7,474.59 lakh compared to ₹249.39 lakh in the prior year. Trade receivables were recorded at ₹414.16 lakh.

Equity capital increased to ₹975.45 lakh from ₹250.45 lakh, following proceeds from the issue of share capital including securities premium amounting to ₹8,315.45 lakh during the year. Reserves and surplus turned positive at ₹7,645.29 lakh, recovering from a deficit of ₹12.65 lakh in FY25. Total liabilities remained low at ₹44.78 lakh, with borrowings at ₹15.50 lakh.

What the Numbers Show

The financial data reveals a strategic shift from operations-led growth to capital-raising activities. While revenue from operations declined by approximately 33% year-on-year, the company generated substantial cash inflows through equity issuance. The surge in other income, specifically interest income, contributed significantly to the bottom line, indicating that the newly raised capital is beginning to yield returns. The reclassification of share warrants as equity, noted in the revised filing, further underscores the structural changes in the company’s capital base during this period.